AJ

Abhishek Jain

Active Director Whole-Time Director DIN 00969226
DIN 00969226 First appointment Feb 1995 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since Feb 1995
Shareholding value •••• Premium profile

About Abhishek Jain

Data last updated:

Abhishek Jain is a Whole-Time Director at Erawat Pharma Limited (since 2003), Director at Jhanjhari Sons Leasing And Investment Pvt Ltd (since 1995) and Director at Swasti Kalyan Foundation (since 2026), and holds 2 more current directorships. The companies operate in Healthcare, Financial Services and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹78.38 Cr; the largest is Erawat Pharma Limited at ₹78.37 Cr (FY 2025). Earlier, Abhishek Jain was a Director at Comsyn International Private Limited (2022–2025).

DIN 00969226
Primary Designation Whole-Time Director
Industry Healthcare
First Appointment 02 Feb 1995
Oldest Company Age 33 yrs
Largest company Erawat Pharma Limited · ₹78.37 Cr (FY 2025)
Combined revenue ₹78.38 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Erawat Pharma Limited U02423MP1993PLC007538
Whole-Time Director11 Jul 20031993₹78.37 Cr (FY 2025)Active
Director02 Feb 19951995₹12,329 (FY 2025)Active
Swasti Kalyan Foundation U94990MP2026NPL084932
Director20 Jun 20262026Active
Anant Formulations Private Limited U24239MP2006PTC018866
Director11 Jan 20252006Active
Anant Pharmacs Private Limited U28290MP2024PTC071189
Director10 May 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Comsyn International Private Limited U24290MP2022PTC060283
Director07 Apr 20222022₹9 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Erawat Pharma Limited
Jhanjhari Sons Leasing And Investment Pvt Ltd
Anant Formulations Private Limited
Anant Pharmacs Private Limited
Premium access

Shareholding and investment profile for Abhishek Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abhishek Jain

Abhishek Jain currently holds 5 directorships: Erawat Pharma Limited (Whole-Time Director, since 11 Jul 2003, revenue ₹78.37 Cr (FY 2025)); Jhanjhari Sons Leasing And Investment Pvt Ltd (Director, since 02 Feb 1995, revenue ₹12,329 (FY 2025)); Swasti Kalyan Foundation (Director, since 20 Jun 2026); Anant Formulations Private Limited (Director, since 11 Jan 2025); Anant Pharmacs Private Limited (Director, since 10 May 2024).

Abhishek Jain was first appointed on 02 Feb 1995 as Director at Jhanjhari Sons Leasing And Investment Pvt Ltd. The most recent appointment on record is 20 Jun 2026 at Swasti Kalyan Foundation.

The 2 current companies of Abhishek Jain that report revenue have a combined latest revenue of ₹78.38 Cr: Erawat Pharma Limited ₹78.37 Cr (FY 2025); Jhanjhari Sons Leasing And Investment Pvt Ltd ₹12,329 (FY 2025).

Abhishek Jain held 1 earlier board appointment: Comsyn International Private Limited (Director, 07 Apr 2022 to 12 Jun 2025).

The current boards of Abhishek Jain's companies include Abhijeet Jain (Erawat Pharma Limited), Amit Jain (Erawat Pharma Limited), Devindar Singh Sodhi (Erawat Pharma Limited), Hemchandra Jain (Erawat Pharma Limited), Meena Jain (Erawat Pharma Limited), Vasant Raj Solanki (Erawat Pharma Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available